CClinicalTrials.gg
WithdrawnNCT03082157Updated Apr 23, 2021

Mighty Men Nashville: A Faith-Based Weight Loss Program to Address Cancer Disparities

An interventional study of Mighty Men Intervention in Weight Loss, sponsored by Vanderbilt University. Withdrawn at 1 site in United States. Open to male participants aged 35 Years to 77 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-04-23.

Sponsored by Vanderbilt University · Not applicable, Interventional, and Treatment

Why this study was withdrawn
Transfer of grant to new institution
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
35 Years to 77 Years
Sex
Male
01

Study summary

Mighty Men is a 6-month faith-based weight-loss intervention for obese African American men 35-74 years old being conducted in Nashville, TN.

Read the detailed description

Mighty Men is a 6-month faith-based weight-loss intervention for obese African American men 35-74 years old. The investigators will conduct this intervention in African American faith-based organizations because these organizations have the opportunity to consistently reach more African American men than any other institution in the African American community. African American faith-based organizations have historically served as a trusted institution for filling gaps in health and social services, including cancer prevention and control programs, within their natural role and function in the African American community. Additionally, African American faith-based organizations are important resources and sources of information for large numbers of middle-aged and older African American men, including those who are not members of a faith-based organization. Though African American men attend faith-based organization's at lower rates than African American women, men constitute 40% of the congregation membership among the largest denominations serving African Americans.

Mighty Men includes: (a) tailored goals/ messages, (b) self-monitoring, (c) small group training and education and (d) educational and community-based information and resources. There are three specific aims for the proposed study:

Specific Aim 1 is to compare the efficacy of Mighty Men to an attention control group in a cluster-randomized clinical trial of 448 African American men. The investigators hypothesize that men in faith-based organizations assigned to the intervention group will have lost more weight than men in faith-based organizations assigned to the comparison group at 6-months, and they will maintain greater weight loss than men in the control group 3-months post intervention.

Specific Aim 2 is to compare changes in cancer risk behaviors (e.g., healthy eating and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., perceived social support, autonomous motivation) at 6-months and 3-months post intervention between Mighty Men and comparison participants. The investigators hypothesize that men assigned to Mighty Men will demonstrate and maintain greater improvements in eating and physical activity and psychosocial mediators than those randomized to the attention control group.

Specific Aim 3 is to examine the impact of Mighty Men on the faith-based organizations that participate in the intervention. The investigators will conduct a rigorous process and impact evaluation to determine the extent of program reach, efficacy, adoption, implementation and maintenance (RE-AIM) in African American faith-based organizations in the intervention condition. Also, investigators hypothesize that faith-based organizations assigned to the intervention will demonstrate greater perceived efficacy to conduct and sustain health ministries for African American men and improvements in all areas of the RE-AIM framework than faith-based organizations randomized to the comparison group.

02

Conditions studied

  • Weight Loss
03

In context

Body Weight

1,223 studies on the registry are indexed under Body Weight; 132 are open to participants now.

Browse Body Weight studies →

Lead sponsor

Vanderbilt University is the lead sponsor of 508 studies on the registry; 19 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
35 Years to 77 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

  • 35-77 at enrollment
  • Black/African American
  • Male; Less than 400 pounds
  • BMI: 27-50
  • Fluent in english
  • provides informed consent

Exclusion criteria

Exclusion Criteria:

  • Pre-existing condition that prohibits at least moderate physical activity
  • Serious medical condition that is likely to hinder accurate measurement of weight
  • a condition for which weight loss is contraindicated
  • a condition that would cause weight loss
  • Prior (2 years) or planned (6 months) bariatric surgery
  • Chronic use of medications that are likely to cause weight gain or cause weight loss
  • No cell phone or land-line phone
  • Participant in another obesity, eating or physical activity program or study
  • Psychiatric hospitalization or in-patient substance abuse treatment in the past 12 months
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Mighty Men Intervention

    Mighty Men weight-loss intervention including health education and exercise during small group sessions

    Behavioral: Mighty Men Intervention

  • No intervention
    Comparison

    Exercise-only small group sessions

Interventions

  • BehavioralMighty Men Intervention

    African American men assigned to this condition will receive: tailored goals/ messages, self-monitoring, small group meetings and educational and community-based information and resources.

06

What researchers measure

Primary outcomes

  1. Weight Loss

    The Primary outcome is change in weight loss at 6-months post-baseline.

    Time frame: 6 months post-baseline

Secondary outcomes

  1. Dietary patterns

    Dietary patterns will be assessed using tools to measure fruit and vegetable intake and fat intake. Fruit and vegetable intake will be assessed using servings of fruits and vegetables consumed per day assessed with two brief frequency measures.

    Time frame: 6 months post-baseline

07

Study locations

1 site
  • Vanderbilt University
    Nashville, Tennessee 37232, United States
08

References and documents

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 23, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03082157
Lead sponsor
Vanderbilt University
Collaborators
American Cancer Society, Inc.
Responsible party
Derek Griffith (Associate Professor, Vanderbilt University) — Principal investigator
First posted
Mar 17, 2017
Start date
Oct 27, 2017
Primary completion
Jun 30, 2021 (estimated)
Completion
Jun 30, 2021 (estimated)
Last update
Apr 23, 2021

Study contacts

Derek Griffith, PhD
principal investigator · Vanderbilt University
Emily C Jaeger, MPH
study director · Vanderbilt University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion